Background {#Sec1}
==========

The 16p13.11 locus is a genomic hotspot especially rich in low-copy repeats. These highly homologous DNA sequences are more likely to form copy number mutations through non-allelic homologous recombination \[[@CR1]\]. The deletions of 16p13.11 are associated with a wide spectrum of disorders including schizophrenia, autism, mental retardation, intellectual disability, epilepsy, and mild microcephaly \[[@CR2]--[@CR6]\]. The 16p13.11 region contains a core set of genes including *NDE1*, the most important candidate gene for the neurodevelopmental phenotypes associated with the 16p13.11 microdeletions. *NDE1* encodes the nuclear distribution factor E-homolog 1 (nudE) protein that localizes to the centrosome and mitotic spindle poles, interacting with the cytoplasmic dynein complex and Lissencephaly-1 (LIS1) \[[@CR7], [@CR8]\]. This protein plays a crucial role in microtubule organization, mitosis and neuronal migration, essential for the process of mammalian encephalisation and human cerebral cortex growth \[[@CR9]\].

To date, several cases of autosomal recessive extreme microcephaly caused by *NDE1* mutations have been reported. Herein we report that a patient, with severe congenital microcephaly, had 16p13.11 deletion containing *NDE1* gene combined with a novel *NDE1* mutation on the non-deleted homolog. We also compared the clinical phenotypes of all patients so far reported with *NDE1* mutations.

Case presentation {#Sec2}
=================

The CARE guidelines were followed in this case. The patient is an 8 months old male that had been diagnosed with extreme microcephaly. The patient was the first child of healthy, non-consanguineous parents, delivered after a 37 weeks gestation by cesarean section. The mother had a spontaneous abortion history after a 12 weeks gestation. The patient displayed microcephaly at birth but the physical parameters were not available. At the age of 8 months, physical examination showed severe microcephaly (Fig. [1a](#Fig1){ref-type="fig"}) with head circumference was 32 cm, 9.6 SD below the mean, marked hypertonia on his extremities, and global developmental delay. Magnetic resonance imaging scans showed the agenesis of the corpus callosum, enlargement of the posterior lateral ventricles, and a simplified gyral pattern of the cerebral cortex with scarce and wide gyri in parietal and occipital lobes (Fig. [1b](#Fig1){ref-type="fig"}). Electroencephalography showed slow background activity without epileptiform discharge.Fig. 1The typical phenotype and laboratory results. The patient at 8 months of age showed severe microcephaly (**a**). MRI showed the agenesis of the corpus callosum, enlargement of the posterior lateral ventricles, and a simplified gyral pattern of the cerebral cortex (**b**). The Diagram of chromosome 16 and the 1.22 M microdeletion on 16p13.11 in the patient detected by CMA (**c** and **d**). The *NDE1* sequence chromatogram of the patient and his parents, and arrows show the 2 base-pairs changes (**e**)

Informed consent was obtained from the parents and the study protocols were reviewed and approved by the medical ethics committee of Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology. Genomic DNA was extracted from peripheral blood using E.Z.N.A. ® MicroElute Genomic DNA Kit (Omega Bio-tek) from the patient and his parents. The samples from the patient and his parents were studied by the InfiniumOmniZhongHua-8 DNA Analysis BeadChip (Illumina), using for CNVs analysis larger than 30 Kb. CMA found that the patient had a 1.22 Mb deletion (hg19:15,070,916--16,292,323) on 16p13.11 inherited from his phenotypically normal mother (Fig. [1d](#Fig1){ref-type="fig"}). The deleted region contains 20 genes, including *ABCC1*, *ABCC6*, *FOPNL*, *MPV17L*, *MYH11*, *NDE1* and *NTAN1*. This boy had severe congenital microcephaly resembling that described in those patients with homozygous mutations in *NDE1* gene \[[@CR9]--[@CR12]\], so we attempted to detect genetic mutations in *NDE1* by performing Sanger Sequencing. The *NDE1* coding exons and flanking intronic sequences of the samples were amplified by PCR and then sequenced by Sanger sequencing using standard methods. Sequences were compared with normal reference sequences for *NDE1* (NCBI reference number NM_001143979.1, NP_001137451.1). The analysis identified a c.555_556GC \> CT mutation in *NDE1* on the non-deleted homolog, inherited from his phenotypically normal father (Fig. [1e](#Fig1){ref-type="fig"}). The 2 bp nucleotide change results in a missense mutation (p.K185 N) and a stop codon (p.Q186X).

Discussion and conclusion {#Sec3}
=========================

We reported an 8-month patient with severe microcephaly, who harbored maternal 16p13.11 deletion combined with a paternal *NDE1* mutation. To date, 14 patients from 8 families with microcephaly involved *NDE1* gene have been reported, and these patients manifested severe congenital microcephaly, profound intellectual disability, and early onset seizure \[[@CR9]--[@CR12]\].

Microcephaly is a cortical malformation disorder characterized by severe impairment in brain development, small brain size, and a substantial reduction in neuronal number. Several genes have been identified to cause this condition, such as *ASPM*, *WDR62*, *CDK5RAP2*, *CENPJ*, *SIL*, and *BRIT1* \[[@CR13]--[@CR15]\], and these genes are involved in proliferation of the progenitor cells by affecting centrosome, mitotic spindle assembly, and cell cycle progression. NDE1-associated microcephaly is much more severe than the forms caused by defects in these genes, and patients with *NDE1* mutations often exhibit neuronal lamination defects, such as a simplified gyral structure or lissencephaly \[[@CR9]--[@CR12]\], and *NDE1* might have multiple roles in neocortical development.

Table [1](#Tab1){ref-type="table"} showed a comparison of the clinical findings of our patient with those cases reported previously \[[@CR9]--[@CR12]\]. All patients had mental retardation, severe microcephaly, and corpus callosum agenesis. Ventricular enlargement was presented in all patients except that Paciorkowski et al. did not describe this issue in their study. All but our patient displayed hypoplastic cerebellum or a proportionate reduction in the size of cerebellum, and epilepsy occurred in most of patients. Currently, it is unclear why the cerebellum of our patient normally appeared in brain MRI. These two mutations in our case, being inherited from their healthy heterozygous parents, were predicted to produce truncated proteins or deleted allele. As previously reported, immunoblot assay did not show detectable NDE1 protein in patient lymphoblast and, whereas the heterozygous parents showed \~50% reduction in protein level, suggesting the instability of mutant protein and subsequent degradation \[[@CR10]\].Table 1A comparison of clinical features of patients with NDE1 deletion and/or mutationsBakircioglu et al.Alkuraya et al.Guven et al.Paciorkowski et al.Present workCharacteristicsF1 (P1-P4)F2 (P5)F3 (P6)F4 (P7-P8)F5 (P9-P10)F6 (P11-P12)P13P14P15EthnicityPakistaniPakistaniTurkishSaudi ArabianSaudi ArabianSlovakCaucasianCaucasianChineseNumber of patients3 males & 1 female1 male1 male2 females1 male & 1 female1 male & 1 female1 male1 maleSurvival and reported agedied in the first 5 years of lifealive,NAalive,7 years, 5.5 yearsalive,3.5 years, NAalive,19 years,17 yearsalive,15 yearsdied at the age of 10 yearsalive,8 monthsPostnatal growth delay------++++++Mental retardation+++++++++Microcephaly+++++++++Corpus callosum Agenesis+++++++++Ventricular enlargement++++++NANA+CerebellumHypoplasticHypoplasticHypoplasticProportionate reductionProportionate reductionHypoplasticProportionate reductionNAnormalSeizures+++--+++single seizure during infancy--Muscle toneNANANAincreaseddecreasedNANANAincreasedprominent broad nasal bridgeNANANA+++NANA+Genetic mutationsc.684_685delAC (hm)c.684_685delAC (hm)c.83 + 1G \> T (hm)c.684_685delAC (hm)c.733dupC (hm)c.-43\_ + 83del (hm)c.130C \> T 16p13.11 deletionc.908_909delGA 16p13.11 deletionc.555_556GC \> CT 16p13.11 deletionAmino acid changeP229WfsX85P229WfsX85A29QfsX114P229WfsX85L245PfsX70null alleleR44XR303TfsX11K185N&Q186X*F* family, *P* patient; +, present; −, absent; *NA* not announced, *Hm* homozygotes

*NDE1* consists of 10 exons and a consensus start codon is located within exon 3 (NM_001143979.1) (Fig. [2a](#Fig2){ref-type="fig"}). Human NDE1 is a protein with 335 amino acids, harboring self-association domain, LIS1 interaction domain, and the C-terminal conserved domain (Fig. [2b](#Fig2){ref-type="fig"}). The C-terminal domain is essential for centrosomal localization of NDE1 and for its interaction with CENP-F (centromere protein F) and dynein \[[@CR16]--[@CR18]\]. LIS1 is essential for neural progenitor division and cortical migration, and its genetic mutations cause Miller-Dieker syndrome \[[@CR19], [@CR20]\]. CENP-F, a nuclear matrix component localizing at kinetochores during mitosis, is required for kinetochore localization of NDE1, LIS1, and Dynein \[[@CR18]\]. Cytoplasmic dynein is a multisubunit complex involved in a variety of cellular functions, including mitotic spindle control, checkpoint regulation, transport of organelles, and directed nuclear and cell migration \[[@CR16], [@CR17], [@CR21]\]. The corrected localization and activation of the dynein complex require the presence of many adaptors, such as CENP-F, LIS1, and NDE1. All these proteins work together to link spindle microtubes to kinetochores, being responsible for mitotic cell division. Recent studies have found that NDE1 is required in cell cycle progression and postmitotic neuronal migration, and NDE1 inhibition caused substantial numbers of radial glia progenitor cells' nuclei to become arrested by impairing primary cilium dynamics, apical nuclear migration, and entry into mitosis \[[@CR22]\]. All these findings could explain the defects in NDE1 contribute to extreme micrpcephaly and other neurodevelopmental conditions.Fig. 2The diagram of human *NDE1* (NM_001143979.1). The coding sequences are shown in black and all the reported mutations are labeled (**a**). The predicted NDE1 protein derived from the mutations (**b**)

To date, several mutations in NDE1 have been reported. Bakircioglu et al. and Alkuraya et al. reported three distinct homozygous frameshift mutations of NDE1, c.83 + 1G \> T (p.A29QfsX114), c.684_685delAC (p.P229WfsX85) and c.733dupC (p.L245PfsX70) \[[@CR9], [@CR10]\]. The c.83 + 1G \> T leads to the formation of a novel splice site and to a frameshift after NDE1 exon 3, and the novel open reading frame would be predicted to maintain the N-terminal 28 native amino acids followed 113 novel amino acids \[[@CR9]\]. The mutant protein completely lost the conserved C-terminal domain, including interacting domains with CENP-F and dynein, and the centrosomal localization domain, the majority of LIS1 binding domain as well \[[@CR9]\]. The c.684_685delAC resulted in a premature stop codon at position 313, and the truncated protein lost the highly conserved C-terminal CENP-F and dynein interaction domain, and also failed to present at the centrosome. However, the mutant protein would be predicted to interact with LIS1 \[[@CR9]\]. The c.733dupC resulted in a truncated protein with 244 native amino acids of the wild-type protein on the N terminus followed by 69 abnormal amino acids. The consequence of this mutation is similar to that of c.684_685delAC, which have been proved in vitro studies \[[@CR9], [@CR10]\], and these truncated mutant proteins failed to bind to the dynein complex and to localize properly to the centrosome. Guven et al. identified a homozygous deletion that encompasses NDE1 exon 3 containing the initiation codon, predicted to result in a null allele \[[@CR11]\]. Paciorkowski et al. describe two patients with inherited deletions of 16p13.11 encompassing the entire NDE1 gene on one allele combined with a nonsense mutation (p.R44X) or a frameshift mutation (p.R303TfsX11) in the non-deleted NDE1 \[[@CR12]\]. Our patient had the deletion of the entire NDE1 gene on one allele combined with a c.555_556GC \> CT on the non-deleted homolog, resulting in a missense mutation (p.K185 N) and a nonsense mutation (p.Q186X). The nonsense mutation is predicted to cause protein truncation in the C-terminal domain of NDE1. If stable, the truncated protein may fail to localize properly to the centrosome due to the loss of domains interacting with CENP-F and dynein. This heterozygote of c.555G \> C (p.K185 N) and c.556C \> T was found to be only presented in one case in East Asian among in populations with more than 120,000 individuls, including East asian, African, Latino, European, etc. in genome aggregation database (<http://gnomad.broadinstitute.org/>), respectively. There was no corresponding literature about these two variants, and it is unclear whether they were presented in one person. There is no report in the first Asian Diploid genome (<http://yh.genomics.org.cn>/).

In, conclusion, we reported a NDE1 genetic mutation combined with 16q13.11 microdeletion in a boy with extreme microcephaly. To our knowledge, this is the first Chinese reported with microcephaly caused by NDE1 mutations. Our findings enrich the understanding of NDE1 mutations and the associated phenotypes. It is warranted to perform mutation screening in NDE1 gene for patients with severe micropcephaly.

Nomenclature {#Sec4}
============

Nucleotide symbol {#Sec5}
-----------------

*A* adenosine*C* cytidine*G* guanosine*T* thymidine*U* uridine

Amino acid residue symbol {#Sec6}
-------------------------

*A* Alanine*K* Lysine*L* Leucine*N* Asparagine*P* Proline*Q* Glutamine*R* Arginine*T* Threonine*W* Tryptophan*X* stop codon

ABCC1

:   ATP binding cassette subfamily C member 1

ABCC6

:   ATP binding cassette subfamily C member 6

ASPM

:   abnormal spindle microtubule assembly

bp

:   base pairs

BRIT1

:   BRCA1 C terminus repeat inhibitor of hTERT

CDK5RAP2

:   CDK5 regulatory subunit associated protein 2

CENP-F

:   centromere protein F

CENPJ

:   centromere protein J

CMA

:   Chromosomal Microarray Analysis

CNVs

:   copy number variations

del

:   deletion

dup

:   duplication

FOPNL

:   FGFR1OP N-terminal like

fs

:   frameshift

Kb

:   kilobase(s) or 1000 bp

LIS1

:   Lissencephaly-1

MPV17L

:   MPV17 mitochondrial inner membrane protein like

MYH11

:   myosin heavy chain 11

NDE1

:   nuclear distribution factor E-homolog 1

NTAN1

:   N-terminal asparagine amidase

PCR

:   Polymerase Chain Reaction

SD

:   standard deviation

SIL

:   STIL, centriolar assembly protein

WDR62

:   WD repeat domain 62
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